Conmed/$CNMD
1D1W1MYTD1Y5YMAX
Capital at risk
About Conmed
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
- Ticker
- $CNMD
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 3,900
- Headquarters
- Largo, United States
- Website
- www.conmed.com
Conmed Metrics
BasicAdvanced
$1.4B
25.55
$1.84
0.93
$0.20
1.70%
Price and volume
Market cap
$1.4B
Beta
0.93
52-week high
$53.66
52-week low
$31.44
Average daily volume
319K
Dividend rate
$0.20
Financial strength
Current ratio
1.484
Quick ratio
0.608
Long term debt to equity
0.631
Total debt to equity
0.801
Dividend payout ratio (TTM)
21.91%
Interest coverage (TTM)
5.12%
Profitability
EBITDA (TTM)
227.461
Gross margin (TTM)
55.58%
Net profit margin (TTM)
4.12%
Operating margin (TTM)
11.18%
Effective tax rate (TTM)
32.12%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
4.14%
Return on equity (TTM)
5.53%
Valuation
Price to earnings (TTM)
25.551
Price to revenue (TTM)
1.052
Price to book
1.35
Price to tangible book (TTM)
-4.41
Price to free cash flow (TTM)
10.736
Free cash flow yield (TTM)
9.31%
Free cash flow per share (TTM)
4.382
Dividend yield (TTM)
0.43%
Forward dividend yield
1.70%
Growth
Revenue change (TTM)
3.42%
Earnings per share change (TTM)
-48.00%
3-year revenue growth (CAGR)
6.39%
10-year revenue growth (CAGR)
6.44%
3-year earnings per share growth (CAGR)
-13.54%
10-year earnings per share growth (CAGR)
11.51%
3-year dividend per share growth (CAGR)
-37.00%
10-year dividend per share growth (CAGR)
-12.94%
What the Analysts think about Conmed
Analyst ratings (Buy, Hold, Sell) for Conmed stock.
Analyst projections of the future price of Conmed stock.
Conmed Financial Performance
Revenues and expenses
Conmed Earnings Performance
Company profitability
Upcoming events
No upcoming events
Conmed News
AllArticlesVideos
CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
Business Wire3 weeks ago
CONMED Q2 Earnings Call Highlights
MarketBeat2 months ago
CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula
Business Wire2 months ago
Funds containing Conmed
AllUSDGBPEUR
Fund name | Fund size | $CNMD weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.08% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.